(VIANEWS) – ELIS (ELIS.PA), NAVAMEDIC (NAVA.OL), ORKLA (ORK.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ELIS (ELIS.PA)
77.2% sales growth and 9.02% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.19.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 15.82. Meaning, the purchaser of the share is investing €15.82 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.02%.
Volume
Today’s last reported volume for ELIS is 63289 which is 80.55% below its average volume of 325478.
More news about ELIS.
2. NAVAMEDIC (NAVA.OL)
17.8% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.36. Meaning, the purchaser of the share is investing kr31.36 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
More news about NAVAMEDIC.
3. ORKLA (ORK.OL)
17.8% sales growth and 12.71% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr5.37.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 14.53. Meaning, the purchaser of the share is investing kr14.53 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Moving Average
ORKLA’s value is below its 50-day moving average of kr79.25 and below its 200-day moving average of kr78.42.
Volume
Today’s last reported volume for ORKLA is 108667 which is 88.97% below its average volume of 986056.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 1.5% and positive 16.7% for the next.
More news about ORKLA.
4. PERNOD RICARD (RI.PA)
7.9% sales growth and 13.85% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. Pernod Ricard SA was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €8.8.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 18.41. Meaning, the purchaser of the share is investing €18.41 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.85%.
Sales Growth
PERNOD RICARD’s sales growth is 7.9% for the present quarter and 7.9% for the next.
Moving Average
PERNOD RICARD’s value is below its 50-day moving average of €163.86 and way below its 200-day moving average of €188.75.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 24, 2023, the estimated forward annual dividend rate is 4.7 and the estimated forward annual dividend yield is 2.88%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 12.14B for the twelve trailing months.
More news about PERNOD RICARD.
5. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.2. Meaning, the purchaser of the share is investing kr23.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 2.4.
Volume
Today’s last reported volume for VISTIN PHARMA is 23604 which is 30.1% above its average volume of 18142.
Moving Average
VISTIN PHARMA’s value is above its 50-day moving average of kr22.62 and above its 200-day moving average of kr22.18.
More news about VISTIN PHARMA.
6. ODFJELL DRILLING (ODL.OL)
5.1% sales growth and 17.1% return on equity
Odfjell Drilling Ltd. owns and operates mobile offshore drilling units primarily in Norway and Namibia. The company operates in two segments, Own Fleet and External Fleet. It offers management services to other owners of drilling units, such as operational management, regulatory requirements management, marketing, contract negotiations and client relations, and operation and mobilization preparation services. The company was founded in 1914 and is headquartered in Aberdeen, the United Kingdom. Odfjell Drilling Ltd. is a subsidiary of Odfjell Partners Holding Ltd.
Earnings Per Share
As for profitability, ODFJELL DRILLING has a trailing twelve months EPS of kr9.99.
PE Ratio
ODFJELL DRILLING has a trailing twelve months price to earnings ratio of 3.9. Meaning, the purchaser of the share is investing kr3.9 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.1%.
Yearly Top and Bottom Value
ODFJELL DRILLING’s stock is valued at kr39.00 at 16:20 EST, below its 52-week high of kr41.90 and way higher than its 52-week low of kr23.00.
Volume
Today’s last reported volume for ODFJELL DRILLING is 515220 which is 63.28% above its average volume of 315528.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ODFJELL DRILLING’s EBITDA is 37.19.
Moving Average
ODFJELL DRILLING’s worth is above its 50-day moving average of kr36.71 and way higher than its 200-day moving average of kr30.90.
More news about ODFJELL DRILLING.
